PreferredStockChannel
Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Sun, October 24, 7:23 AM
| This Slide: #2 of 565 |
Slide #2. Cidara Therapeutics, Inc. — Preferred Stock Offering
Company:
Cidara Therapeutics, Inc. (NASDAQ:CDTX)
Date announced:
10/8/2021
Shares Offered:
14,838,706
Date of Pricing:
10/8/2021
Price Per Share:
$1.55
Preferred Stock Offering Details:
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 14,838,706 shares of its common stock at a price to the public of $1.55 per share and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share. The gross proceeds to Cidara from these offerings, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $35.0 million. In addition, with respect to the common stock offering, Cidara has granted the underwriters a 30-day option to purchase up to an additional 2,225,805 shares of its common stock at the public offering price of $1.55 per share less underwriting discounts and commissions. The offerings are expected to close on or about October 13, 2021, subject to satisfaction of customary closing conditions. The closing of each offering is not contingent upon the closing of the other.
Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of therapeutics designed for patients facing fungal or viral infections. Co.'s primary product candidate is rezafungin acetate, an intravenous formulation of a echinocandin. Rezafungin is being developed as a once-weekly therapy for the first-line treatment and prevention of invasive fungal infections. In addition, Co. is using its Cloudbreak® platform to develop Antiviral Conjugates, for the prevention and treatment of influenza and other viral infections, including RSV, HIV and the SARS-CoV-2 strains causing COVID-19.
Open the CDTX Page at Preferred Stock Channel »
|
|||||||||||||||||||||
|
|
Open the CDTX Page at Preferred Stock Channel (in a new window) »
 Free CDTX Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 95th percentile
(ranked higher than approx. 95% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
 |
